A wireless implantable device for the treatment of cancerous tumors
The researchers took advantage of this property to develop an attractive and obvious goal: to design a drug delivery system that targets a low-oxygen environment for cancer treatment. Anticancer drugs are directed at these areas, with the goal of effectively killing cancer cells.
The previous approach of targeting hypoxia in cancer cells Some challenges, including varying levels of hypoxia in solid tumors. However, this problem has been solved by a Chinese research team that has developed an oxygen consuming battery that is implanted in the environment of the cancer cell. Details of this achievement were announced in the latest issue of the magazine
"Science Advances".This battery is self-charging and increases the level of hypoxia, making it easier for killer drugs to target the tumor site more precisely and effectively. This development represents an important advance in the field of targeting cancer, and may open new avenues for improving the efficacy of targeted therapies for cancer.Is characterized by cancer cells Generally with low oxygen levels, this condition is known as"hypoxia".
Researchers have created in hospitals University of California, Los Angeles (UCLA) Significant progress after their development and study of a small implantable device called the "SymphNode". This device is designed to target and attack cancer cells using T cells in the human body. Laboratory experiments conducted on mice showed, and were published in the scientific journal "Nature Biomedical Engineering"، Impressive results, as this device contributed to the treatment of solid tumors, reducing their spread, and preventing the formation of any new tumors. Thus, this development contributed to an increase in the survival rate of mice.
This exciting discovery could pave the way for the development of new technologies to treat solid tumors in humans. It may be for the device "SymphNode" A huge impact in the field of cancer treatment, and it may represent a quantum leap in the use of immunotherapies and enhance the body's immune response to fight cancer.
Resistance of solid tumors to cancer treatments is one of the major challenges in the field of oncology therapy. Solid tumors rely on multiple mechanisms for treatment resistance, including exploitation of T cells (T-cell) In the body. Solid tumors surround themselves with white blood cells "infiltrated immunization"، This suppresses the body's immune response to cancer.
This infiltrative immunization means that solid tumors suppress the immune system's response to attack them, thus blocking the full effectiveness of immunotherapies such as T-cell therapy. (T-cell therapy). Therefore, it is important to study and develop new tools and techniques to overcome this resistance and enhance the effectiveness of treatment against solid tumors.
Disrupting T cells to treat cancerous tumors can cause serious problems. Therefore, treatment strategies that target T cells must be carefully considered to avoid negative impact on the whole body.
T cells have a critical role in regulating and protecting the body's immune response, including controlling the devouring of cancer cells and regulating tissue inflammation. If these cells are inactivated uncontrollably, the immune balance may be disturbed and the body may escalate its unwanted devouring of healthy cells. This may cause harm and damage to the organs of the body, such as: colon .liver .the heart and others.
Hence, researchers and scientists should direct their efforts towards developing treatment strategies that target cancerous tumors effectively, without negatively affecting T-cells and their normal function. Scientists aim to find a balance between targeting tumors and maintaining immune balance and its basic functions in the body.
Confirms co-author Manish Butt (Manish Butte) University of California Los Angeles (UCLA) The importance of considering regulatory T cells within the tumor and their elimination as an important key in the treatment of solid tumors. Richard Stehm has pointed out (Richard Stiehm)، Professor of Allergy, Immunology and Pediatric Rheumatology at UCLA، All solid tumors contain high levels of T cells that limit our ability to treat cancer. Indeed, the presence of T cells within tumors is one of the factors that contribute to the difficulty of treating cancer and is the main reason behind the high rate of cancer-related deaths.
This research direction underscores the importance of developing novel strategies to manipulate T cells and overcome immunization of solid tumors. Researchers and scientists are exploring and developing innovative techniques and methodologies to target these cells and bypass the resistance mechanisms of solid tumors. This research aims to improve the effectiveness of treatment and increase the survival rate for patients with cancer.
that device SymphNode The small one that uses biodegradable materials such as alginate (Alginate) It stimulates the body's immune response to fight cancer in multiple ways. The device is surgically implanted right next to the tumor and performs specific functions to enhance the body's defense against cancer.
One of the functions of the system is to gradually release a specific drug to inhibit the regulatory T cells that surround the tumour. This aims to reduce the effect of these T cells that can limit the effectiveness of the immune response to fight cancer.
At the same time, the device also enhances and attracts cancer-fighting immune cells to fight tumors without causing health problems to the body. The device configuration is somewhat similar lymph nodes Which is a suitable environment for cancer-fighting immune cells. In addition, the device contains pores lined with antibodies that boost the activity of these immune cells.
This approach aims to stimulate a local immune response at the tumor site and specifically promote immune destruction of tumors, and thus could have exciting prospects in cancer treatment. However, more research and trials need to be done to evaluate the long-term efficacy and safety of this device and to determine its applicability in humans.
The results of the tests on mice that the researchers conducted using the SymphNode device are amazing and show its potential benefits in treating cancer. In the first group of mice with breast cancer, tumor reduction was observed in 80% of cases and a complete reduction in proliferation was observed by 100%. It is worth noting that untreated mice in this group experienced metastasis of cancer to the brain and lymph nodes and died within a few weeks.
In addition, the researchers note that implanting the device next to a breast cancer tumor can stop the growth of another cancerous tumor elsewhere in the body. This means that the device can work to prevent the formation of new cancerous tumors, and its effect may extend to multiple areas in the body.
These promising results indicate the possibility of using the SymphNode device as a potential tool for therapeutic intervention in the treatment of cancerous tumours. However, research and trials must continue to assess the device's long-term efficacy and safety and to determine the best ways to apply it in humans.
The results of the study in the second cohort of mice with skin cancer reflect the amazing benefits of using the SymphNode device. It was noted that the device reduced the tumor by 100% in this group, and reduced tumors to difficult-to-detect levels in 40% of cases.
Another positive outcome of this study is the significantly increased survival rate of mice. It was observed that the survival rate of treated mice using the device was approximately twice that of untreated mice.
These results reinforce the promising idea of using the SymphNode device as a potential therapeutic tool skin cancer. However, research and development must continue to achieve a deeper understanding of the device's efficacy, to improve it, and to trial it on a larger scale to confirm the results and its application in humans.
According to the study conducted using the SymphNode device on infected mice breast cancer، The researchers observed that the treated mice were able to resist the growth of a second cancerous tumor 100 days after the first treatment. This effect is attributed to activity T cells The memory that was activated during the treatment of the first tumor and that recognizes the cancer if it comes back. This indicates the possibility of reducing the risk of cancer returning.
Usually, there are few existing treatments that boost memory T cells and prevent tumors from coming back. Therefore, these results are promising and may open new horizons in the field of cancer treatment and constitute an important shift in the design of future treatments. However, application of this therapeutic exploration in humans requires additional studies and clinical trials to achieve the device's full efficacy and safety.
The research team's focus is on developing a SymphNode device for cancer treatment, with the goal of making this technology available to patients in the future. To that end, the team is licensing the technology to a company Symphony Biosciences affiliated with the California Institute of Technology NanoSystems .
The licensing process aims to transfer the technology and knowledge gained from the research to the commercial sector, where the company develops, manufactures and prepares the device for clinical use. This authorization requires compliance with scientific and regulatory standards necessary to ensure the safety and effectiveness of the device when used in humans.
It is important that more research and clinical trials are conducted to determine the efficacy and safety of a device SymphNode before it could be made available as a cancer treatment in the future. Licensing the technology to a specialized company is part of this development process.
Symphony is currently developing a smaller version of the SymphNode, which will be injectable. This potential version is intended as an addition to chemotherapy or first-stage treatments for some different types of cancer. The company also aims to initially apply this technology to triple-negative breast cancer, which is an aggressive form of cancer that lacks the targeted treatment options currently available.
Post a Comment